HIGHLIGHTS
- who: Veselina Stefanova from the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, Sandra ARotman have published the research: suPAR to Risk-Stratify Patients With Malaria, in the Journal: (JOURNAL) of 10/06/2022
- what: The authors report an overview of urokinase/urokinase-type plasminogen activator receptor (uPA/uPAR) biology, review what is known about suPAR in pediatric malaria, and discuss the ability of suPAR to predict disease outcome and its potential as a druggable target. Given that dysregulated endothelial and immune activation contributes to the pathogenesis of severe falciparum malaria . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.